Thought Leadership Regulatory Decision on Class of Alzheimer’s Drugs Has the Potential to Upend Drug Development as We Know It Feb 10, 2022
Announcements Statement by MassBio’s Chief of Corporate Affairs Zach Stanley on Senate Passage of Senate Bill 2651, An Act Relative to Pharmaceutical Access, Costs and Transparency Feb 10, 2022
Thought Leadership Using our Collective Strength to Continue Bridging the Opportunity Gap Feb 10, 2022
Thought Leadership 97% of surveyed life science companies plan to implement hybrid work models for the long-term Feb 08, 2022
In the News Boston Herald: Massachusetts biopharma companies’ venture capital investment jumped 70% in 2021: report Jan 28, 2022
Thought Leadership The Massachusetts Biopharma Industry Set Another Record-Breaking Funding Year. Here’s What that Means for the Future of our Cluster Jan 27, 2022
